urbazon/E+ by way of Getty Pictures
Regeneron (NASDAQ:REGN) reported optimistic up to date outcomes from a Section 1/2 examine of its gene remedy DB-OTO within the therapy of profound genetic listening to loss in kids on account of sure variants of the OTOF gene.
The corporate stated 48-week outcomes from
